Related Experiment Videos
High grade primary breast lymphoma: is it a different clinical entity?
Christophe Fruchart1, Yves Denoux, Jacques Chasle
1Department of Clinical Oncology, Centre François Baclesse, Caen, France.
Breast Cancer Research and Treatment
|September 21, 2005
Summary
High-grade primary breast lymphoma (PBL) has a poor prognosis, with only 38% survival. Chemotherapy, particularly with CHOP or ACVBP regimens, significantly improves survival rates to 73% for these rare lymphomas.
Area of Science:
- Oncology
- Hematology
- Pathology
Background:
- Primary breast lymphoma (PBL) is a rare malignancy with an unclear prognosis.
- High-grade PBL, predominantly Diffuse Large B-cell Lymphoma (DLBCL), presents unique treatment challenges.
Purpose of the Study:
- To evaluate the outcomes of high-grade primary breast lymphoma.
- To identify prognostic factors and optimize treatment strategies for PBL.
Main Methods:
- Retrospective analysis of 19 high-grade PBL cases.
- Treatment modalities included local therapy, chemotherapy (CHOP/ACVBP), and radiotherapy.
- Immunohistochemical analysis for Bcl6 and CD10 expression.
Main Results:
- Overall actuarial survival was 38%.
- Patients receiving chemotherapy (n=11) had a 73% overall survival rate (median follow-up 57 months).
- Local treatment alone resulted in a poor outcome (3/4 deaths).
- Co-expression of Bcl6 and CD10 correlated with a better prognosis.
- Central nervous system recurrences were observed.
- Radical mastectomy was associated with increased treatment failure.
Conclusions:
- Chemotherapy-based regimens significantly improve survival in high-grade PBL.
- CNS prophylaxis should be considered, even without clear poor prognostic factors.
- Avoid radical mastectomy in favor of less invasive approaches to prevent treatment failure.